Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Canagliflozin: Impact on Health Status, Quality of Life, and Functional Status in Heart Failure

Next Previous
Trial Profile

Canagliflozin: Impact on Health Status, Quality of Life, and Functional Status in Heart Failure

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Canagliflozin (Primary)
  • Indications Heart failure
  • Focus Registrational; Therapeutic Use
  • Acronyms CHIEF-HF
  • Sponsors Janssen Research & Development

Most Recent Events

  • 01 Jun 2023 Trial design assessing the operational structure and novel strategies employed in a completely DCT by summarizing the recruitment, enrollment, engagement, retention, and follow-up processes used in the execution of the trial at 18 centers published in the Journal of Cardiac Failure
  • 01 Apr 2022 Results published in the Nature Medicine
  • 07 Dec 2021 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top